1 Report Prologue
2 Introduction
2.1 Definition 13
2.2 Scope of the Study 13
2.3 List of Assumptions 14
2.4 Market Structure 14
3 Research Methodology
3.1 Research Process 16
3.2 Primary Research 17
3.3 Secondary Research 18
3.4 Market Size Estimation 19
3.5 Forecast Model 19
4 Market Dynamics
4.1 Overview 21
4.2 Drivers 22
4.2.1 Growing demand for oral thin film drugs 22
4.2.2 Increasing geriatric population 22
4.3 Restraints 23
4.3.1 Drugs which irritate the mucosa or causes ulcers cannot be administrated by the oral route 23
4.3.2 Drug with a small dosage form can only be administrated 23
4.3.3 Drugs which are unstable at buccal pH cannot be administered 23
4.3.4 Stringent regulations 24
4.4 Opportunities 24
4.4.1 Introduction of oral thin film drugs in developing regions 24
4.4.2 Increasing investments in research & innovations 24
5 Market Factor Analysis
5.1 Porter’s Five Forces Model 26
5.1.1 Bargaining Power of Suppliers 26
5.1.2 Bargaining Power of Buyers 27
5.1.3 Threat of New Entrants 27
5.1.4 Threat of Substitutes 27
5.1.5 Intensity of Rivalry 27
5.2 Value Chain Analysis 28
5.2.1 Research & Development 28
5.2.2 Manufacturing 28
5.2.3 Distribution & Sales 28
5.2.4 Post-Sales Monitoring 28
5.3 Investment Opportunities 29
5.4 Macroeconomic Indicators 29
6 Global Oral Thin Film Drugs Market by Product
6.1 Overview 31
6.2 Fast Dissolving Buccal Film 32
6.3 Sublingual 32
7 Global Oral Thin Film Drugs Market by Disease Indication
7.1 Overview 34
7.2 Schizophrenia 35
7.3 Migraine 36
7.4 Opioid Dependence 36
7.5 Nausea and Vomiting 37
8 Global Oral Thin Film Drugs Market by Distribution Channel
8.1 Overview 39
8.2 Retail Pharmacies 40
8.3 Online Drug Stores 40
8.4 Hospital Pharmacies 41
9 Global Oral Thin Film Drugs Market by Region
9.1 Overview 43
9.2 Americas 44
9.2.1 North America 46
9.2.1.1 US 47
9.2.1.2 Canada 48
9.2.2 South America 49
9.3 Europe 51
9.3.1 Western Europe 53
9.3.1.1 Germany 54
9.3.1.2 France 55
9.3.1.3 UK 56
9.3.1.4 Italy 57
9.3.1.5 Spain 58
9.3.1.6 Rest of Western Europe 59
9.3.2 Eastern Europe 60
9.4 Asia-Pacific 62
9.4.1 Japan 64
9.4.2 China 65
9.4.3 India 66
9.4.4 Australia 67
9.4.5 South Korea 68
9.4.6 Rest of Asia-Pacific 69
9.5 Middle East & Africa 70
9.5.1 Middle East 72
9.5.2 Africa 73
10 Competitive Landscape
10.1 Overview 75
10.2 Company Share Analysis 75
11 Company Profiles
11.1 Johnson & Johnson Services, Inc. 77
11.1.1 Company Overview 77
11.1.2 Financial Overview 77
11.1.3 Products Offering 77
11.1.4 Key Developments 78
11.1.5 SWOT Analysis 78
11.1.6 Key Strategy 78
11.2 Pfizer Inc. 79
11.2.1 Company Overview 79
11.2.2 Financial Overview 79
11.2.3 Products/Services Offering 79
11.2.4 Key Developments 80
11.2.5 SWOT Analysis 80
11.2.6 Key Strategy 80
11.3 CURE Pharmaceutical 81
11.3.1 Financial Overview 81
11.3.2 Products/Services Offering 81
11.3.3 Key Developments 81
11.3.4 SWOT Analysis 82
11.3.5 Key Strategy 82
11.4 Novartis AG 83
11.4.1 Company Overview 83
11.4.2 Financial Overview 83
11.4.3 Products Offering 84
11.4.4 Key Developments 84
11.4.5 SWOT Analysis 84
11.4.6 Key Strategy 84
11.5 LTS Lohmann Therapie-Systeme AG 85
11.5.1 Company Overview 85
11.5.2 Financial Overview 85
11.5.3 Products Offering 85
11.5.4 Key Developments 85
11.5.5 SWOT Analysis 86
11.5.6 Key Strategy 86
11.6 GlaxoSmithKline Plc (GSK) 87
11.6.1 Company Overview 87
11.6.2 Financial Overview 87
11.6.3 Products Offering 88
11.6.4 Key Developments 88
11.6.5 SWOT Analysis 88
11.6.6 Key Strategy 88
11.7 Indivior plc 89
11.7.1 Company Overview 89
11.7.2 Financial Overview 89
11.7.3 Products Offering 90
11.7.4 Key Developments 90
11.7.5 SWOT Analysis 90
11.7.6 Key Strategy 90
12 Appendix
12.1 Discussion Blue Print 92